Two pharmacists at the 2025 APhA Annual Meeting debate the role of continuous glucose monitoring (CGM) for non-insulin users, highlighting evolving guidelines, emerging clinical evidence, cost and coverage challenges, and the need for further research to justify widespread adoption.
Read More
APhA 2025: Pharmacists Can Prescribe Contraceptives in 30 States and the District of Columbia
March 22nd 2025Contraceptive options have expanded since 1960, with pharmacists today playing a growing role as prescribers of contraception and studies showing the benefit of pharmacist-driven contraception clinics.
Read More
APhA 2025: A Pharmacist’s Guide to Culturally Competent and Inclusive Care
March 21st 2025Sally Arif, PharmD, BCCP, discusses her presentation on the critical role of pharmacists in addressing health disparities by improving communication, fostering cultural competence, and promoting pharmacoequity.
Watch
Elevated Non-HDL Cholesterol a Stronger Indicator of Major Cardiovascular Events Compared With LDL-C
March 21st 2025Non-high-density lipoprotein cholesterol was found to be more effective at predicting cardiovascular events such as stroke, myocardial outcomes, heart failure, and others compared with low-density lipoprotein cholesterol.
Read More
Experts: Vast Disparities in Opioid Prescribing Observed for Minority Communities in Past Decade
March 21st 2025Allison Ju-Chen Hu, PhD and Yuhua Bao, PhD describe results of their landmark study that found significant differences in opioid prescriptions in racially and ethnically minoritized communities.
Read More
Guselkumab Receives FDA Approval for Adults With Moderately to Severely Active Crohn Disease
March 21st 2025The new indication for guselkumab in Crohn disease builds off a previous approval in ulcerative colitis, providing patients a treatment option for the major forms of inflammatory bowel disease.
Read More
FDA Approves Vutrisiran to Reduce Cardiovascular Death, Hospitalizations in Patients With ATTR-CM
Published: March 21st 2025 | Updated: March 21st 2025Vutrisiran becomes the first and only therapeutic FDA-approved to treat cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults.
Read More
Allo-SCT, Myeloablative Conditioning With Busulfan/Fludarabine Improves Survival in Myelofibrosis
March 20th 2025Allogeneic stem cell transplant (allo-SCT) conditioning with busulfan/fludarabine with thiotepa and posttransplant cyclophosphamide induced improved 2-year progression-free survival and overall survival in patients with myelofibrosis, especially older adults.
Read More